US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, on Wednesday announced positive top-line results from a Phase 3 trial evaluating its 9-valent Human Papillomavirus (HPV) vaccine, GARDASIL 9, in Japanese males.
The vaccine demonstrated efficacy in reducing the incidence of anogenital persistent infection caused by nine HPV types.
Merck plans to submit these findings to regulatory authorities in Japan and worldwide. The company is also conducting a confirmatory Phase 3 trial to assess GARDASIL 9's effectiveness in preventing HPV-related oral persistent infection.
Avacta Group presents positive Phase 1 data for AVA6000 at ESMO Congress
ValiRx subsidiary Inaphaea signs co-marketing agreement with Spanios
Sareum Holdings secures patent allowance for SDC-1801 in China
TME Pharma presents promising NOX-A12 trial results at ESMO Congress 2024
Kine Sciences reports first patient dosed in KINE-101 Phase 1b/2a clinical study
Alume Biosciences names new chief commercial officer
Senhwa Biosciences' Silmitasertib gains rare paediatric disease designation for Neuroblastoma
Lilly expands manufacturing footprint in Ireland
Sanofi, RadioMedix and Orano Med partner on rare cancer treatment
Johnson & Johnson receives approval from FDA for TREMFYA (guselkumab)